Loading
Inflammatory Bowel Disease / Gastrointestinal Motility and Disorders · Journal article
British Journal of Healthcare and Medical Research · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a retrospective case series of six patients with prior restorative IPAA who presented with pouchitis within 6 weeks of initiating GLP-1RA therapy. The temporal clustering raises a hypothesis that GLP-1RA-mediated changes in gastrointestinal motility may promote pouchitis in this surgically altered population, but the small sample, lack of controls, and absence of mechanistic data prevent causal inference.
Retrospective case series. Patients with a history of total proctocolectomy and restorative IPAA who were admitted with pouchitis and had initiated GLP-1RA therapy within the preceding 6 weeks.. Intervention: GLP-1 receptor agonist therapy initiated within 6 weeks before admission. n = 6.
Six patients (three men, three women) with prior total proctocolectomy and restorative IPAA presented with pouchitis after recent GLP-1RA initiation Mean age 37 years (range 27–49 years) Mean BMI 40.2 kg/m²
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should be aware that GLP-1RA initiation may be temporally associated with pouchitis onset in IPAA patients, warranting careful monitoring of pouch function when prescribing GLP-1RAs to this population. However, this is a hypothesis from a small uncontrolled case series and does not yet constitute evidence of causation or quantified risk.
A small retrospective case series (n=6) describing a temporal association between GLP-1RA initiation and pouchitis in surgically altered anatomy; raises a hypothesis rather than establishing causation or providing quantified risk.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should be aware that GLP-1RA initiation may be temporally associated with pouchitis onset in IPAA patients, warranting careful monitoring of pouch function when prescribing GLP-1RAs to this population. However, this is a hypothesis from a small uncontrolled case series and does not yet constitute evidence of causation or quantified risk.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for obesity and metabolic disease and may exert anti-inflammatory effects in inflammatory bowel disease. However, their effects on gastrointestinal motility may have distinct implications in patients with surgically altered intestinal anatomy. We evaluated the temporal relationship between recent GLP-1RA initiation and pouchitis in patients with a prior restorative ileal pouch–anal anastomosis (IPAA). Methods: We retrospectively reviewed patients with a history of total proctocolectomy and restorative IPAA who were admitted with pouchitis between January 2016 and January 2026 and had initiated GLP-1RA therapy within the preceding 6 weeks. Demographic characteristics, body mass index (BMI), and clinical features were descriptively evaluated. Results: Six patients met inclusion criteria, including three men and three women. The mean age was 37 years (range, 27–49 years), and the mean BMI was 40.2 kg/m². All patients had recently initiated GLP-1RA therapy before admission for pouchitis. The temporal association between GLP-1RA exposure and the development of pouch-related symptoms raises the possibility of an association between altered gastrointestinal transit and pouch inflammation. Discussion: Although GLP-1RAs may exert beneficial anti-inflammatory effects, pharmacologically mediated gastrointestinal hypomotility may have opposing consequences in patients with an ileal pouch. Altered transit, luminal stasis, and changes in the pouch microbial environment may contribute to mucosal inflammation. Further investigation is warranted to clarify the relationship between GLP-1RA therapy, intestinal motility, and pouchitis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.